80 related articles for article (PubMed ID: 19632173)
1. A new therapeutic target for leukemia comes to the surface.
Ritchie DS; Smyth MJ
Cell; 2009 Jul; 138(2):226-8. PubMed ID: 19632173
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells.
Majeti R
Oncogene; 2011 Mar; 30(9):1009-19. PubMed ID: 21076471
[TBL] [Abstract][Full Text] [Related]
3. Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro.
Wang Y; Yin C; Feng L; Wang C; Sheng G
Genet Mol Res; 2015 May; 14(2):5630-41. PubMed ID: 26125761
[TBL] [Abstract][Full Text] [Related]
4. [CD47 and leukemia stem cells].
Cheng QS; Wang XB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1088-91. PubMed ID: 20723335
[TBL] [Abstract][Full Text] [Related]
5. Self inhibition of phagocytosis: the affinity of 'marker of self' CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels.
Tsai RK; Rodriguez PL; Discher DE
Blood Cells Mol Dis; 2010 Jun; 45(1):67-74. PubMed ID: 20299253
[TBL] [Abstract][Full Text] [Related]
6. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.
Jaiswal S; Jamieson CH; Pang WW; Park CY; Chao MP; Majeti R; Traver D; van Rooijen N; Weissman IL
Cell; 2009 Jul; 138(2):271-85. PubMed ID: 19632178
[TBL] [Abstract][Full Text] [Related]
7. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.
Majeti R; Chao MP; Alizadeh AA; Pang WW; Jaiswal S; Gibbs KD; van Rooijen N; Weissman IL
Cell; 2009 Jul; 138(2):286-99. PubMed ID: 19632179
[TBL] [Abstract][Full Text] [Related]
8. CD47 promotes both phosphatidylserine-independent and phosphatidylserine-dependent phagocytosis of apoptotic murine thymocytes by non-activated macrophages.
Nilsson A; Oldenborg PA
Biochem Biophys Res Commun; 2009 Sep; 387(1):58-63. PubMed ID: 19559673
[TBL] [Abstract][Full Text] [Related]
9. Soluble extracellular domains of human SIRPα and CD47 expressed in Escherichia coli enhances the phagocytosis of leukemia cells by macrophages in vitro.
Lin Y; Yan XQ; Yang F; Yang XW; Jiang X; Zhao XC; Zhu BK; Liu L; Qin HY; Liang YM; Han H
Protein Expr Purif; 2012 Sep; 85(1):109-16. PubMed ID: 22813925
[TBL] [Abstract][Full Text] [Related]
10. [Effectiveness of anti-CD47 antibody and Ara-C combination targeting therapy NOD/SCID mouse of myeloid leukemia].
Wang YC; Feng L; Yin CY; Ma LN; Wei YW; Wang CM; Sheng GY
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jul; 15(7):577-82. PubMed ID: 23866283
[TBL] [Abstract][Full Text] [Related]
11. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.
Kikushige Y; Akashi K
Ann N Y Acad Sci; 2012 Aug; 1266():118-23. PubMed ID: 22901263
[TBL] [Abstract][Full Text] [Related]
12. Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPα Facilitate Apoptotic Cell Clearance by Macrophages.
Lv Z; Bian Z; Shi L; Niu S; Ha B; Tremblay A; Li L; Zhang X; Paluszynski J; Liu M; Zen K; Liu Y
J Immunol; 2015 Jul; 195(2):661-71. PubMed ID: 26085683
[TBL] [Abstract][Full Text] [Related]
13. A fully human anti-CD47 blocking antibody with therapeutic potential for cancer.
Zeng D; Sun Q; Chen A; Fan J; Yang X; Xu L; Du P; Qiu W; Zhang W; Wang S; Sun Z
Oncotarget; 2016 Dec; 7(50):83040-83050. PubMed ID: 27863402
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 4 promotes phagocytosis of murine leukemia cells counteracted by CD47 upregulation.
Peña-Martínez P; Ramakrishnan R; Högberg C; Jansson C; Nord DG; Järås M
Haematologica; 2022 Apr; 107(4):816-824. PubMed ID: 33951888
[TBL] [Abstract][Full Text] [Related]
15. Targeting of AML-leukemic stem cells with monoclonal antibodies.
Lee EM; Lock RB
Future Oncol; 2009 Nov; 5(9):1327-30. PubMed ID: 19903061
[No Abstract] [Full Text] [Related]
16. The BALB/c-specific polymorphic SIRPA enhances its affinity for human CD47, inhibiting phagocytosis against human cells to promote xenogeneic engraftment.
Iwamoto C; Takenaka K; Urata S; Yamauchi T; Shima T; Kuriyama T; Daitoku S; Saito Y; Miyamoto T; Iwasaki H; Kitabayashi I; Itoh K; Kishimoto J; Kohda D; Matozaki T; Akashi K
Exp Hematol; 2014 Mar; 42(3):163-171.e1. PubMed ID: 24269920
[TBL] [Abstract][Full Text] [Related]
17. CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models.
Xu JF; Pan XH; Zhang SJ; Zhao C; Qiu BS; Gu HF; Hong JF; Cao L; Chen Y; Xia B; Bi Q; Wang YP
Oncotarget; 2015 Sep; 6(27):23662-70. PubMed ID: 26093091
[TBL] [Abstract][Full Text] [Related]
18. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.
Chen J; Zhong MC; Guo H; Davidson D; Mishel S; Lu Y; Rhee I; Pérez-Quintero LA; Zhang S; Cruz-Munoz ME; Wu N; Vinh DC; Sinha M; Calderon V; Lowell CA; Danska JS; Veillette A
Nature; 2017 Apr; 544(7651):493-497. PubMed ID: 28424516
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells.
Kim D; Wang J; Willingham SB; Martin R; Wernig G; Weissman IL
Leukemia; 2012 Dec; 26(12):2538-45. PubMed ID: 22648449
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent inhibitory effect of CD47 in macrophage uptake of IgG-opsonized murine erythrocytes.
Olsson M; Nilsson A; Oldenborg PA
Biochem Biophys Res Commun; 2007 Jan; 352(1):193-7. PubMed ID: 17112468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]